Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
121 hedge funds and large institutions have $407M invested in Merrimack Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 31 increasing their positions, 36 reducing their positions, and 15 closing their positions.
127% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 15
52% more capital invested
Capital invested by funds: $268M → $407M (+$139M)
50% more call options, than puts
Call options by funds: $7.79M | Put options by funds: $5.19M
19% more funds holding
Funds holding: 102 → 121 (+19)
14% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 36
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$11.3M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$10.7M |
| 3 |
Renaissance Technologies
New York
|
+$3.67M |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$3.52M |
| 5 |
Goldman Sachs
New York
|
+$2.97M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$8.02M |
| 2 |
Jennison Associates
New York
|
-$6.46M |
| 3 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$2.6M |
| 4 |
CCA
Catalyst Capital Advisors
Huntington,
New York
|
-$2.27M |
| 5 |
Morgan Stanley
New York
|
-$2.18M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GE
126
General Electric
Evendale,
Ohio
| – | -$222K | -5,610 | Closed |
|
127
Jane Street
New York
| – | -$178K | -4,498 | Closed |
|
|
SCM
128
Stevens Capital Management
Radnor,
Pennsylvania
| – | -$127K | -3,215 | Closed |
|
|
ST
129
Spot Trading
Chicago,
Illinois
| – | -$122K | -2,405 | Closed |
|
|
VKH
130
Virtu KCG Holdings
New York
| – | -$79K | -1,983 | Closed |
|
|
PPA
131
Parametric Portfolio Associates
Seattle,
Washington
| – | -$73K | -1,837 | Closed |
|
|
SB
132
Suntrust Banks
Atlanta,
Georgia
| – | -$70K | -1,790 | Closed |
|
133
SG Americas Securities
New York
| – | -$67K | -1,694 | Closed |
|
|
WAM
134
Wolverine Asset Management
Chicago,
Illinois
| – | -$27.1K | -534 | Closed |
|
|
TRCT
135
Tower Research Capital (TRC)
New York
| – | -$9K | -236 | Closed |
|
136
Ameriprise
Minneapolis,
Minnesota
| – | +$203 | +4 | New |
|
MACK Hedge Fund Activity: Q2 2014 in Review
121 of the 3,480 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2014, worth a combined $407M — up 52% from $268M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new MACK positions and 15 closed out — a net gain of 19 holders — while 31 added to existing stakes and 36 trimmed.
The largest buyer was Millennium Management, adding an estimated $11.3M. The largest seller was State Street, cutting an estimated $8.02M.
- 121 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2014, up from 102 in Q1 2014.
- Funds reported $407M of Merrimack Pharmaceuticals, Inc. stock for Q2 2014, up 52% quarter-over-quarter.
- 34 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2014 and 15 closed out, a net change of +19 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2014 was Millennium Management, an estimated $11.3M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2014 was State Street, an estimated $8.02M sold.
Based on aggregated 13F filings for Q2 2014.